Last reviewed · How we verify
Asofarma de México S.A de C.V. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PLA (Panto+Levoflox+Azithro) | PLA (Panto+Levoflox+Azithro) | phase 3 | Combination therapy (proton pump inhibitor + fluoroquinolone + macrolide) | Gastroenterology / Infectious Disease | ||
| CLA (Clarithro+Lanso+Amoxi) | CLA (Clarithro+Lanso+Amoxi) | phase 3 | Antibiotic combination with proton pump inhibitor | H. pylori bacterial ribosomes (clarithromycin); H. pylori cell wall (amoxicillin); gastric H+/K+-ATPase (lansoprazole) | Gastroenterology / Infectious Disease |
Therapeutic area mix
- Gastroenterology / Infectious Disease · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Asofarma de México S.A de C.V.:
- Asofarma de México S.A de C.V. pipeline updates — RSS
- Asofarma de México S.A de C.V. pipeline updates — Atom
- Asofarma de México S.A de C.V. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Asofarma de México S.A de C.V. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/asofarma-de-m-xico-s-a-de-c-v. Accessed 2026-05-17.